Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at an advanced stage due to the absence of symptoms. A key characteristic ...

Symptoms, and Treatment Liver cancer is one of the most challenging forms of cancer, often developing quietly before showing any clear signs. It begins when abnormal cells form in the liver, a vital ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Bayer announced initiation of a phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumours expressing Glypican-3 (GPC3 ...

BAY 3547926 is an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced hepatocellular carcinoma (HCC).

in patients with advanced hepatocellular carcinoma (HCC). Oncofetal protein GPC3 is a membrane-associated proteoglycan which is overexpressed in 70-75% of HCC lesions making it an attractive ...